A meta-analysis of the placebo rates of remission and response in clinical trials of active crohn’s disease

Su, Chinyu, Lichtenstein, Gary R., Krok, Karen, Brensinger, Colleen M., Lewis, James D.·2004·Gastroenterology
DOI 10.1053/j.gastro.2004.01.024

Cited by (212)

Items 101–200 of 212

  1. Prebiotics and Inflammatory Bowel Disease
    Heather Elizabeth Rasmussen, Bruce R. Hamaker · 2017 · Gastroenterology Clinics of North America
  2. What predicts mucosal inflammation in Crohnʼs disease patients?
    Itta M. Minderhoud, Melvin Samsom, Bas Oldenburg · 2007 · Inflammatory Bowel Diseases
  3. Endoscopic monitoring of infliximab therapy in Crohnʼs disease
    Clas-Göran af Björkesten, Urpo Nieminen, Ulla Turunen, Perttu E. T. Arkkila, Taina M. Sipponen, Martti A. Färkkilä · 2010 · Inflammatory Bowel Diseases
  4. Biological therapy targeting the IL-23/IL-17 axis in inflammatory bowel disease
    Bram Verstockt, Gert Van Assche, Séverine Vermeire, Marc Ferrante · 2016 · Expert Opinion on Biological Therapy
  5. A Double-Blind Clinical Trial for Treatment of Crohn's Disease by Oral Administration of Alequeltm, A Mixture of Autologous Colon-Extracted Proteins: A Patient-Tailored Approach
    Maya Margalit, Eran Israeli, Oren Shibolet, Ehud Zigmond, Athalia Klein, Nilla Hemed, James J. Donegan, Elazar Rabbani, Eran Goldin, Yaron Ilan · 2006 · The American Journal of Gastroenterology
  6. Natalizumab for the treatment of Crohn’s disease
    Stephen J. Bickston, Kishor Muniyappa · 2010 · Expert Review of Clinical Immunology
  7. Listening to Placebo in Clinical Trials for Female Sexual Dysfunction
    Andrea Michele Bradford · 2012 · The Journal of Sexual Medicine
  8. Meta-analysis
    Gabriele Capurso, Lucia Cocomello, Umberto Benedetto, Carlo Cammà, Gianfranco Delle Fave · 2012 · Pancreas
  9. The placebo effect and homeopathy
    Marcus Zulian Teixeira, Cristina H.F.F. Guedes, Patrícia V. Barreto, Mílton A. Martins · 2010 · Homeopathy
  10. Aktualisierte S3-Leitlinie „Diagnostik und Therapie des Morbus Crohn“ der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) (Version 4.1) – living guideline
    Andreas Sturm, Raja Narayana Atreya, Dominik Bettenworth, Bernd Bokemeyer, Axel U Dignass, Robert Ehehalt, Christoph-Thomas Germer, Philip Grunert, Ulf Helwig, Karoline Horisberger et al. · 2024 · Zeitschrift für Gastroenterologie
  11. Guidelines for the Management of Crohn's Disease
    Byong Duk Ye, Suk‐Kyun Yang, Sung Jae Shin, Kang‐Moon Lee, Byung Ik Jang, Jae Hee Cheon, Chang Hwan Choi, Young‐Ho Kim, Heeyoung Lee · 2012 · Korean Journal of Gastroenterology
  12. Historical Controls in Randomized Clinical Trials: Opportunities and Challenges
    Kathryn Tayo Hall, Lene Vase, Deirdre Kay Tobias, Hesam Dashti, Jan Vollert, Ted Jack Kaptchuk, Nancy R. Cook · 2020 · Clinical Pharmacology & Therapeutics
  13. C-Reactive Protein: Anti-Placebo or Predictor of Response
    James D. Lewis · 2005 · Gastroenterology
  14. Clinical trials in luminal Crohn's disease: A historical perspective
    Pieter Hindryckx, Filip Baert, Ailsa L Hart, Alessandro Armuzzi, Julián Panés, Laurent Peyrin‐Biroulet · 2014 · Journal of Crohn s and Colitis
  15. The Placebo and Nocebo Responses in Clinical Trials in Inflammatory Bowel Diseases
    Paul Enck, Sibylle Klosterhalfen · 2021 · Frontiers in Pharmacology
  16. Evolving Concepts in Phases I and II Drug Development for Crohn’s Disease
    Vipul Jairath, Barrett G. Levesque, Niels Vande Casteele, Reena Khanna, Mahmoud Hisham Mosli, Pieter Hindryckx, Simon P.L. Travis, Marjolejn Duijvenstein, Jordi Rimola, Julián Panés et al. · 2016 · Journal of Crohn s and Colitis
  17. Targeting nanomedicines in the treatment of Crohn's disease: focus on certolizumab pegol (CDP870)
    Lotte C. Dinesen, Simon P.L. Travis · 2007 · International Journal of Nanomedicine
  18. Bases psiconeurofisiológicas do fenômeno placebo-nocebo: evidências científicas que valorizam a humanização da relação médico-paciente
    Marcus Zulian Teixeira · 2009 · Revista da Associação Médica Brasileira
  19. Meta-Analysis of the Placebo Response in Ulcerative Colitis
    Sagar S. Garud, Alphonso Brown, Adam S. Cheifetz, Emily B. Levitan, Ciarán P. Kelly · 2007 · Digestive Diseases and Sciences
  20. Interconexão entre saúde, espiritualidade e religiosidade
    Marcus Zulian Teixeira · 2020 · Revista de Medicina
  21. Guidelines for the Management of Crohn's Disease
    Byong Duk Ye, Suk‐Kyun Yang, Sung Jae Shin, Kang‐Moon Lee, Byung Ik Jang, Jae Hee Cheon, Chang Hwan Choi, Young-Ho Kim, Heeyoung Lee · 2012 · Intestinal Research
  22. How Rapidly Should Remission Be Achieved?
    Kim L. Isaacs · 2010 · Digestive Diseases
  23. Placebo Response Rate in Clinical Trials of Fistulizing Crohn's Disease: Systematic Review and Meta-analysis
    Alexander Charles Ford, Pavit Luthra, Stephen B. Hanauer, Simon P.L. Travis, M. Scott Harris, Walter Reinisch · 2014 · Clinical Gastroenterology and Hepatology
  24. Clinical, Endoscopic, and Safety Placebo Rates in Induction and Maintenance Trials of Crohn’s Disease: Meta-Analysis of Randomised Controlled Trials
    Ahmed Almradi, Rocío Sedaño, Malcolm Hogan, Guangyong Zou, John K MacDonald, Claire E. Parker, Jurij Hanžel, Eileen Crowley, Siddharth Singh, Geert D’Haens et al. · 2021 · Journal of Crohn s and Colitis
  25. Clinical Trial: The Effects of Emulsifiers in the Food Supply on Disease Activity in Crohn's Disease: An Exploratory Double‐Blinded Randomised Feeding Trial
    Jessica A. Fitzpatrick, Peter R. Gibson, Kirstin M. Taylor, Ellen J. Anderson, Antony B. Friedman, Zaid SM Ardalan, Rebecca L. Smith, Emma P. Halmos · 2025 · Alimentary Pharmacology & Therapeutics
  26. Interpreting Registrational Clinical Trials of Biological Therapies in Adults with Inflammatory Bowel Diseases
    Subrata K. Ghosh, William J. Sandborn, Jean‐Frédéric Colombel, Brian G. Feagan, Remo Panaccione, Stephen B. Hanauer, Stefan Schreiber, Laurent Peyrin‐Biroulet, Séverine Vermeire, Samantha Foster Eichner et al. · 2016 · Inflammatory Bowel Diseases
  27. The IL-12/23/STAT Axis as a Therapeutic Target in Inflammatory Bowel Disease: Mechanisms and Evidence in Man
    Irene Marafini, Erika Angelucci, Francesco Pallone, Giovanni Monteleone · 2015 · Digestive Diseases
  28. Literature-related discovery: common factors for Parkinson’s Disease and Crohn’s Disease
    Ronald Neil Kostoff · 2014 · Scientometrics
  29. Advances in therapeutic approaches to ulcerative colitis and crohn’s disease
    Simon P.L. Travis · 2005 · Current Gastroenterology Reports
  30. Certolizumab Pegol: A TNF-α Antagonist for the Treatment of Moderate-to-Severe Crohn's Disease
    Lisa S. Smith, Michael Nelson, Christian R. Dolder · 2010 · Annals of Pharmacotherapy
  31. Outcomes of placebo therapy in inflammatory bowel disease
    Chinyu G. Su · 2006 · Inflammatory Bowel Diseases
  32. Efficacy of a Digital Personalized Elimination Diet for the Self-Management of Irritable Bowel Syndrome and Comorbid Irritable Bowel Syndrome and Inflammatory Bowel Disease
    Samuel N. Jactel, Joseph M. Olson, Kathleen Y. Wolin, Jordan Brown, Mythili P. Pathipati, Valerie Jagiella, Joshua R. Korzenik · 2022 · Clinical and Translational Gastroenterology
  33. Klinische Bedeutung des Placeboeffektes
    J. Oeltjenbruns, Michael Schäfer · 2008 · Der Anaesthesist
  34. Is the multidisciplinary team essential for the future management of patients with inflammatory bowel disease?
    Alastair C. J. Windsor, Alastair Forbes · 2007 · Colorectal Disease
  35. The Placebo Response Rate in Irritable Bowel Syndrome and Inflammatory Bowel Disease
    Sands, Bruce E. · 2009 · Digestive Diseases
  36. Darvadstrocel in Patients With Crohn’s Disease With Complex Perianal Fistulas: The ADMIRE CD II Phase 3 Randomized Trial
    Jean‐Frédéric Colombel, Damián García‐Olmo, S. Chen, Zuzana Šerclová, David A. Schwartz, S. Wexner, Julián Panés, Chunyuan Wu, Barbara Zhang, Michael Song et al. · 2026 · Gastroenterology
  37. Designing fecal microbiota transplant trials that account for differences in donor stool efficacy
    Scott W. Olesen, Thomas Gurry, Eric J. Alm · 2017 · Statistical Methods in Medical Research
  38. Meta‐analysis: remission and response from control arms of randomized trials of biological therapies for active luminal Crohn’s disease
    Fabio Tinè, Francesca Rossi, Antonella Sferrazza, Ambrogio Orlando, Filippo Mocciaro, Daniela Scimeca, Mirko Olivo, Mario Cottone · 2008 · Alimentary Pharmacology & Therapeutics
  39. A scoping review of placebo and nocebo responses and effects: insights for clinical trials and practice
    Arianna Bagnis, Stefanie H. Meeuwis, Julia W. Haas, Mary O’Keeffe, Elżbieta A. Bajcar, Przemysław Bąbel, Andrea W.M. Evers, Eveliina Glogan, Marek Oleszczyk, Antonio Portolés et al. · 2025 · Health Psychology Review
  40. Treatment sequence network meta-analysis in Crohn’s disease: a methodological case study
    Abhishek Varu, Florence R. Wilson, Peter Dyrda, Maureen Hazel, Brian Hutton, Chris G Cameron · 2019 · Current Medical Research and Opinion
  41. Restraint stress induces and exacerbates intestinal inflammation in interleukin-10 deficient mice
    Koh, Seong-Joon · 2015 · World Journal of Gastroenterology
  42. Rethinking Clinical Trials and Personalized Medicine with Placebogenomics and Placebo Dose
    Vural Özdemir, László Endrényi · 2020 · OMICS A Journal of Integrative Biology
  43. Targeting Leukocyte Trafficking in Inflammatory Bowel Disease
    Nicola J Wyatt, Ally Speight, Christopher James Stewart, John Andrew Kirby, Christopher Andrew Lamb · 2021 · BioDrugs
  44. An analysis of the placebo effect in Crohn’s disease over time
    William Gallahan, D. Case, Richard S. Bloomfeld · 2009 · Alimentary Pharmacology & Therapeutics
  45. Investigational agents for Crohn's disease
    Mario Cottone, Ambrogio Orlando, Sara Renna · 2010 · Expert Opinion on Investigational Drugs
  46. The role of placebo effects in immune-related conditions: mechanisms and clinical considerations
    Rosanne M. Smits, Dieuwke Swaantje Veldhuijzen, Nico Martinus Wulffraat, Andrea W.M. Evers · 2018 · Expert Review of Clinical Immunology
  47. Model-Based Meta-Analysis on the Efficacy of Biologics and Small Targeted Molecules for Crohn’s Disease
    Boran Yu, Libo Zhao, Siyao Jin, Huan He, Jing Zhang, Xiaoling Wang · 2022 · Frontiers in Immunology
  48. Deep Remission in Crohn's Disease: Is It the End of the Placebo Effect?
    Laurent Peyrin‐Biroulet · 2013 · Clinical Gastroenterology and Hepatology
  49. Supportive Therapy in IBD: What Additional Diagnoses and Conditions Must Be Treated?
    Jason M. Swoger, David G. Binion · 2010 · Digestive Diseases
  50. Clinical and genetic factors predicting response to therapy in patients with Crohn's disease
    Marilia L. Cravo, Paula Ferreira, Patrícia Vidal Sousa, Paula Moura-Santos, S. Velho, Lurdes Tavares, J. Ramos de Deus, Paula Ministro, João Pereira da Silva, Luís Correia et al. · 2014 · United European Gastroenterology Journal
  51. Risk–benefit analysis of adalimumab versus traditional non-biologic therapies for patients with Crohnʼs disease
    Edward V. Loftus, Scott J. Johnson, Si-Tien Wang, Eric Qiong Wu, Parvez M Mulani, Jingdong Chao · 2010 · Inflammatory Bowel Diseases
  52. The Case Against Using 5-Aminosalicyclates in Crohnʼs Disease
    Eduard Friedrich Stange · 2005 · Inflammatory Bowel Diseases
  53. Placebo therapy in Crohn's disease
    Sara Renna, Ambrogio Orlando, Filippo Mocciaro, Mario Cottone · 2009 · European Journal of Internal Medicine
  54. An update on medical management on Crohn’s disease
    Andrea Affronti, Ambrogio Orlando, Mario Cottone · 2014 · Expert Opinion on Pharmacotherapy
  55. Certolizumab pegol: an evidence-based review of its place in the treatment of Crohn’s disease
    Gabriele Bianchi-Porro · 2007 · Core evidence
  56. Mesalamine in the treatment of active Crohn’s disease
    Axel U Dignass, Philippe R. Marteau · 2005 · Gastroenterology
  57. Translational research and efficacy of biologics in Crohn's disease: a cautionary tale
    Keil Auer, Robert Trachter, Johan van den Bogaerde, Josep Bassaganya-Riera, Dario R. Sorrentino · 2014 · Expert Review of Clinical Immunology
  58. Modifying T-cell trafficking to the intestinal as a potential management for inflammatory bowel disease
    Ian Craig Lawrance · 2012 · Expert Opinion on Investigational Drugs
  59. Comparative Efficacy of all Available Pharmaceutical Therapies for Moderate to Severe Crohn’s Disease: A Systematic Review and Network Meta-Analysis
    Matthijs Versteegh, Demy L. Idema, Simone A. Huygens, Kevin Jenniskens, Marieke J. Pierik, Tessa E H Römkens, Fiona D M van Schaik, Peter J. Wahab, Linde F. Huis in ’t Veld, Mike P. T. Kusters et al. · 2025 · Gastro Hep Advances
  60. Placebo effects on all‐cause mortality of patients with COVID ‐19 in randomized controlled trials of interleukin 6 antagonists: A systematic review and network meta‐analysis
    Ping‐Tao Tseng, Bing‐Syuan Zeng, Trevor Thompson, Brendon Stubbs, Po‐Ren Hsueh, Kuan‐Pin Su, Yen‐Wen Chen, Tien‐Yu Chen, Yi‐Cheng Wu, Pao‐Yen Lin et al. · 2023 · Psychiatry and Clinical Neurosciences
  61. C-Reactive Protein: Informative or Misleading Marker of Crohnʼs Disease?
    Denis Paul Franchimont · 2007 · Inflammatory Bowel Diseases
  62. A prospective study comparing patient-reported outcomes in Crohn’s disease
    Daniël R. Hoekman, Mark Löwenberg, Gijs R. VAN DEN BRINK, Cyriel Y. Ponsioen, Marc Alexander Benninga, Geert D’Haens · 2019 · European Journal of Gastroenterology & Hepatology
  63. Infliximabe na doença de crohn: experiência clínica de um centro terciário paulista
    Ulysses S. Torres, Geni Satomi Cunrath, Luís Sérgio Ronchi, João Gomes Netinho · 2009 · Revista Brasileira de Coloproctologia
  64. Anti–Tumor Necrosis Factor Therapy in Crohn's Disease: More Information and More Questions About the Long Term
    Charles Noah Bernstein · 2010 · Clinical Gastroenterology and Hepatology
  65. When can we cure Crohn's?
    Gerassimos J. Mantzaris · 2014 · Best Practice & Research Clinical Gastroenterology
  66. How Failure Can Fuel Improvements in Early Drug Development for Inflammatory Bowel Diseases
    Stefan Schreiber, Séverine Vermeire · 2016 · Gastroenterology
  67. Veto on vedolizumab (MLN0002) for Crohnʼs disease
    Daniel C. Baumgart · 2009 · Inflammatory Bowel Diseases
  68. What are the Best Placebo Interventions for the Treatment of Pain?
    Karin Meißner, Klaus Linde · 2013 · Elsevier eBooks
  69. Ensaio clínico quali-quantitativo para avaliar a eficácia e a efetividade do tratamento homeopático individualizado na rinite alérgica perene
    Marcus Zulian Teixeira · 2009
  70. Pharmacometrics: Concepts and Applications to Drug Development
    Mallika Lala, Jogarao V. S. Gobburu · 2010
  71. Complementary and alternative medicine use by cancer patients commencing curative-intent chemotherapy: survey and educational intervention
    Peter James Smith · 2016 · The University of Queensland
  72. New biologics in the management of Crohn’s disease: focus on certolizumab pegol
    Vito Annese · 2009 · Clinical and Experimental Gastroenterology
  73. Diet, Deficiencies, and Inflammatory Bowel Diseases: a Comprehensive Review
    Nicole Cornet, Robert J. Battat · 2023 · Current Treatment Options in Gastroenterology
  74. Surgical Management of Crohn’s Disease
    Paul D. Murphy, T. Papettas · 2014 · Springer eBooks
  75. Emerging drugs to treat Crohn's disease
    Ulrike Strauch, Jürgen Schölmerich · 2010 · Expert Opinion on Emerging Drugs
  76. Methodological Problems in RCTs on IBD
    Mario Cottone, Valeria VC Criscuoli, Irene Modesto, A. Orlando · 2012 · Reviews on Recent Clinical Trials
  77. El efecto placebo y la homeopatía1
    Marcus Zulian Teixeira, Cristina H.F.F. Guedes, Patrícia V. Barreto, Mílton A. Martins · 2014 · Revista Médica de Homeopatía
  78. DEVELOPMENT, EVALUATION AND APPLICATION OF A PEDIATRIC ULCERATIVE COLITIS ACTIVITY INDEX (PUCAI)
    Dan Turner · 2008
  79. Use of Placebo in a Trial of Thalidomide for Pediatric Crohn Disease
    Wael El‐Matary · 2014 · JAMA
  80. CDP870 in Crohnʼs disease: Reconsidering Endpoints
    Trevor A. Winter, Willem J.S. de Villiers, Houssam E. Mardini · 2006 · Inflammatory Bowel Diseases
  81. Are we moving forward in the biological treatment of Crohnʼs disease? time will tell
    Ioannis K. Oikonomou, Bo Shen · 2006 · Inflammatory Bowel Diseases
  82. From the Editor
    Robert Allan · 2006 · Clinical Medicine
  83. Certolizumab pegol in the treatment of Crohn’s disease: evidence from the PRECiSE clinical trial program
    Ian C. Lawrance · 2011 · Clinical Investigation
  84. Utilization and Clinical Outcome Following 5-Aminosalicylate Therapy for Crohn's Disease in Children
    Bella Zeisler · 2018 · Gastroenterology & Hepatology Research
  85. The clinical effect of benesco™ on reflux symptoms: A double‐blind randomized placebo‐controlled trial
    Thijs Kuipers, Renske A. B. Oude Nijhuis, Jeroen M. Schuitenmaker, Albert Jan Bredenoord · 2023 · Neurogastroenterology & Motility
  86. Placebo response and remission rates in randomised trials of induction and maintenance therapy for Crohn’s disease
    Vipul Jairath, Guangyong Zou, Claire E. Parker, John K MacDonald, Mahmoud Hisham Mosli, Turki AlAmeel, Mohammad Al Beshir, Majid Abdularahman Almadi, Talal Al-Taweel, Nathan S. S. Atkinson et al. · 2017 · Cochrane Database of Systematic Reviews
  87. Prévention des récidives de la maladie de Crohn : pourquoi et comment?
    Stéphane Nahon, Cécile Poupardin · 2006 · Acta Endoscopica
  88. Outcomes, Disease Activity Indices and Study Design
    Mark T. Osterman, James D. Lewis, Faten N. Aberra · 2010
  89. Therapeutic Approaches to the Treatment of Crohn's Disease
    Simon P.L. Travis · 2010
  90. Place des nouvelles molécules dans la prise en charge thérapeutique des MICI
    Xavier Roblin · 2006 · Hépato-Gastro & Oncologie Digestive
  91. Efecto placebo en la enfermedad inflamatoria intestinal
    Ignacio Marín‐Jiménez · 2009 · Gastroenterología y Hepatología
  92. Trial discontinuation: lessons for future trial design?
    Veerle J. A. A. Nuij, Colin G. de Haar, C. Janneke van der Woude · 2012 · Clinical Investigation
  93. Is it always necessary to treat CD patients?
    Emma Calabrese, Francesco Pallone · 2008 · Inflammatory Bowel Diseases
  94. Exploration of Post-market Evidence of Effectiveness and Safety of TNF-alpha Inhibitors in Crohn’s and Colitis
    Erika MacDonald · 2015 · uO Research (University of Ottawa)
  95. Cicatrisation muqueuse endoscopique : un nouvel objectif thérapeutique dans les MICI ? Mucosal healing in IBD: a new therapeutic target?
    Xavier Tréton, Yoram Bouhnik · 2008
  96. Probiotics in Crohn's Disease
    Esi S. N. Lamousé-Smith, Athos Bousvaros · 2009 · Humana Press eBooks
  97. Objective Assessment of Clinical Disease Activity
    Edouard J. Louis, Catherine Van Kemseke, Cathérine Reenaers · 2017 · Springer eBooks
  98. ORIGINAL ARTICLES—LIVER, PANCREAS, AND BILIARY TRACT Placebo in Nonalcoholic Steatohepatitis: Insight Into Natural History and Implications for Future Clinical Trials
    Rohit Seth Loomba, ROBERT A. WESLEY, Frank Pucino, Tiebing Liang, David Erwin Kleiner, Joel E. Lavine · 2008
  99. Intestinal-Based Diseases and Peripheral Infection Risk Associated with Gut Dysbiosis: Therapeutic use of Pre- and Probiotics and Fecal Microbiota Transplantation
    Bryan C. Tungland · 2018 · Elsevier eBooks
  100. Biologics and biosimilars in inflammatory bowel disease
    Judith Anne Murphy · 2018 · Nurse Prescribing